Conferences
ASCO GU 2024: Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC
January 28, 2024
ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy
January 28, 2024
ASCO GU 2024: Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC
January 28, 2024
ASCO GU 2024: Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer
January 28, 2024
ASCO GU 2024: Low and High Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study
January 28, 2024
ASCO GU 2024: Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience
January 28, 2024
ASCO GU 2024: Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC
January 28, 2024